6 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2227594/here-s-what-key-metrics-tell-us-about-blueprint-medicines-bpmc-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2227594
Feb 16, 2024 - While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:-4658842931809672919
0
https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2226283
Feb 14, 2024 - Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
zc:-118470773275190829
0
https://www.zacks.com/stock/news/2223454/blueprint-medicines-bpmc-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223454
Feb 08, 2024 - Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:5159943749987509367
0
https://www.zacks.com/stock/news/2210972/what-makes-blueprint-medicines-bpmc-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2210972
Jan 16, 2024 - Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zc:-2931134598065702017
0
https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923
Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
zc:3749578308170351338
0
https://www.zacks.com/stock/news/2197568/blueprint-bpmc-gets-ec-nod-for-ayvakit-expanded-use-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197568
Dec 13, 2023 - Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.
zc:-8113738612440637649
0